Clinical trial
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
NCT00406809 · AbbVie (prior sponsor, Abbott), Industry · Completed
Key facts
| NCT number | NCT00406809 |
|---|---|
| Title | A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies |
| Official title | A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies |
| Lead sponsor | AbbVie (prior sponsor, Abbott), Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphoid Leukemia, Lymphoid Malignancies, Non-Hodgkin's Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Peripheral T-cell Lymphoma |
| Intervention type | Drug |
| Interventions | ABT-263 |
| Enrollment | 81 |
| Start date | Nov 1, 2006 |
| Primary completion | Oct 1, 2016 |
| Completion | Oct 1, 2016 |
| First posted | Dec 4, 2006 |
| Last update posted | Aug 2, 2021 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: